Loading clinical trials...
Loading clinical trials...
Phase 2/3 Study of Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Conditions
Interventions
Part A: Upamostat 200 mg
Part A: Upamostat 400 mg
+2 more
Locations
17
United States
Beautiful Minds Clinical Research
Cutler Bay, Florida, United States
Research in Miami Inc.
Hialeah, Florida, United States
Angels Clinical Research Institute
Miami, Florida, United States
South Florida Research Phase I-IV, Inc.
Miami Springs, Florida, United States
Great Lakes Research Group
Bay City, Michigan, United States
Henry Ford Hospital, emergency department
Detroit, Michigan, United States
Start Date
February 16, 2021
Primary Completion Date
December 28, 2021
Completion Date
December 28, 2021
Last Updated
June 6, 2024
NCT04525716
NCT03188796
NCT04527315
NCT06355232
NCT05191420
NCT04611243
Lead Sponsor
RedHill Biopharma Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions